InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,100.00
(
2.07%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.62
(
0.06%
)
Bitcoin
66,694.10
(
0.43%
)
Post# of 11554
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

StocksDiva

Send PM Follow Ignore
Followers 378
Posts 20728
Boards Moderated 2
Alias Born 03/28/2010

StocksDiva

Re: StocksDiva post# 11420

Monday, 04/14/2014 8:40:17 AM

Monday, April 14, 2014 8:40:17 AM

Post# of 11554
BIND Therapeutics barasertib data positive, says JMP Securities
JMP Securities notes that pre-clinical studies of BIND's barasertib showed enhanced anti-tumor activity and reduced bone marrow toxicity. The firm thinks the company could overcome the need for lengthy drug infusion and high rates of febrile neutropenia, shown in a previous studiy, by extending the half-life of the drug. The firm reiterates a $30 price target and Outperform rating on the stock.
http://www.theflyonthewall.com/permalinks/entry.php/BINDid1992466/BIND-BIND-Therapeutics-barasertib-data-positive--says-JMP-Securities


StocksDiva Bio Bin board

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up